Novel Drug Delivery Systems (NDDS)

New Chemical Entities (NCE)

They include small molecules and nucleic acid therapeutics focusing on novel targets

PROTAC

It enables complete target protein degradation, overcomes drug resistance, and addresses traditionally undruggable targets

RIPTAC

It adopts a "lock-and-kill" strategy to selectively eliminate tumor cells

Cyclic Peptide

Designed for protein-protein interactions (PPI) and other undruggable targets

BA-huMab^® Fully Human Antibody Platform

It covers almost all genes in the human antibody κ light chain variable region and in the human heavy chain variable region (IgM and IgG1);

No humanization required, this platform enables high antibody affinity and low immunogenicity;

It’s been validated in more than 10 investigational antibody programs.

Bispecific / Multispecific Antibody / Probody Platform

On this platform, we develop next-generation PD-(L)1-based ICIs (e.g., PD-1/IL-2 immunocytokines) to address low response rates and resistance associated with conventional ICIs;

Multiple bispecific and multispecific antibody programs are under development to treat cancers and autoimmune diseases;

It reduces on-target toxicity in non-tumor tissues through Probody and masking peptide technologies, thereby expanding the therapeutic window.

Antibody-Drug Conjugate (ADC) Platform

It utilizes novel payloads with excellent therapeutic potential;

Glycosite-specific conjugation is used to improve the safety profile;

On this platform, we develop novel bispecific ADCs to address highly heterogeneous tumors;

We also develop innovative dual-payload ADCs to overcome drug resistance;

Multiple bispecific ADC and dual-payload ADC programs are under development;

Probody ADCs are under development.